Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Statins intolerance"'
Autor:
Mangas, Alipio1,2,3 (AUTHOR) jsrguezroca@gmail.com, Pérez-Serra, Alexandra4,5 (AUTHOR) aperez@idibgi.org, Bonet, Fernando1,2 (AUTHOR) elena.alonso@gm.uca.es, Muñiz, Ovidio6 (AUTHOR) ovidiomuniz@gmail.com, Fuentes, Francisco7,8 (AUTHOR) ffuentes@uco.es, Gonzalez-Estrada, Aurora6 (AUTHOR) aglezestrada@gmail.com, Campuzano, Oscar4,5,8,9 (AUTHOR) ocampuzano@idibgi.org, Rodriguez Roca, Juan Sebastian3 (AUTHOR), Alonso-Villa, Elena1,2 (AUTHOR), Toro, Rocio1,2 (AUTHOR) fbonetmartinez@gmail.com
Publikováno v:
International Journal of Molecular Sciences. Aug2022, Vol. 23 Issue 15, p8146-8146. 18p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alipio Mangas, Alexandra Pérez-Serra, Fernando Bonet, Ovidio Muñiz, Francisco Fuentes, Aurora Gonzalez-Estrada, Oscar Campuzano, Juan Sebastian Rodriguez Roca, Elena Alonso-Villa, Rocio Toro
Publikováno v:
International Journal of Molecular Sciences, 2022, vol. 23, núm. 15, p. 8146
Articles publicats (IdIBGi)
DUGiDocs – Universitat de Girona
instname
International Journal of Molecular Sciences; Volume 23; Issue 15; Pages: 8146
Articles publicats (IdIBGi)
DUGiDocs – Universitat de Girona
instname
International Journal of Molecular Sciences; Volume 23; Issue 15; Pages: 8146
Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of morbidity and mortality in Western societies. Statins are the first-choice therapy for dislipidemias and are considered the cornerstone of ASCVD. Statin-associated muscle sympto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a81f9f3963548f96fbcf92cf0e06eadf
https://hdl.handle.net/10668/21179
https://hdl.handle.net/10668/21179
Publikováno v:
In Atherosclerosis August 2021 331:e164-e164
Publikováno v:
Atherosclerosis. 331:e164
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::217bfdfb81b13d21325ae430fccda795
https://doi.org/10.1016/j.atherosclerosis.2021.06.499
https://doi.org/10.1016/j.atherosclerosis.2021.06.499
Autor:
Ana Torres do Rego, Pablo Demelo-Rodríguez, Alejandro Parra-Virto, Jesús Millán Núñez-Cortés, Luis A. Álvarez-Sala
Publikováno v:
Clínica e Investigación en Arteriosclerosis (English Edition). 30:268-270
Many patients with familial hypercholesterolaemia (FH) or in secondary prevention situations and with statin intolerance do not achieve LDL-C targets, and require treatment with PCSK9 inhibitors (iPCSK9) and ezetimibe. The case is presented on a pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d36d0766982be3cb987afdde9fc96700
https://doi.org/10.1016/j.artere.2018.11.002
https://doi.org/10.1016/j.artere.2018.11.002
Autor:
Marina Blanco-Ruiz, Laura Amaya-Pascasio, Reyes de Torres Chacón, María Josefa Álvarez Soria, Antonio Arjona-Padillo, María Magdalena Carrillo Bailén, Rodrigo Milán Pinilla, Irene Pérez Ortega, Belén Sánchez Rodríguez, Luis Andrade Zumárraga, Roberto Valverde Moyano, Manuel Payán Ortiz, Alba María Castillo Fernández, Cristina Del Toro Pérez, Pablo González Bustos, Eduardo Agüera Morales, Purificación Sánchez López, Beatriz Hidalgo Martín, Ricardo Roa Chamorro, Javier Fernández Pérez, María Victoria Mejías Olmedo, Patricia Martínez-Sánchez
Publikováno v:
Atherosclerosis Plus, Vol 45, Iss , Pp 32-38 (2021)
Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine cl
Externí odkaz:
https://doaj.org/article/b020ee4ca2c84b4e8348c9ae45697a6f
Autor:
Rodrigo Milán Pinilla, María Magdalena Carrillo Bailén, Marina Blanco-Ruiz, María Josefa Álvarez Soria, Belén Sánchez Rodríguez, Patricia Martínez-Sánchez, Laura Amaya-Pascasio, Roberto Valverde Moyano, Irene Pérez Ortega, María Victoria Mejías Olmedo, Pablo González Bustos, Javier Fernández Pérez, Purificación Sánchez López, Reyes de Torres Chacón, Eduardo Agüera Morales, Manuel Payán Ortiz, Luis Andrade Zumárraga, Antonio Arjona-Padillo, Alba María Castillo Fernández, Cristina Del Toro Pérez, Beatriz Hidalgo Martín, Ricardo Roa Chamorro
Publikováno v:
Atherosclerosis Plus, Vol 45, Iss, Pp 32-38 (2021)
Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2169b116cf8566849cf4241055ffa2d5
http://www.sciencedirect.com/science/article/pii/S2667089521000419
http://www.sciencedirect.com/science/article/pii/S2667089521000419
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kiełbowski, Kajetan1 (AUTHOR), Żychowska, Justyna1 (AUTHOR), Bakinowska, Estera1 (AUTHOR) kajetan.kielbowski@onet.pl, Pawlik, Andrzej1 (AUTHOR) pawand@poczta.onet.pl
Publikováno v:
Diagnostics (2075-4418). Sep2024, Vol. 14 Issue 17, p1981. 19p.